Golden
Aglaia Biomedical Ventures

Aglaia Biomedical Ventures

Aglaia is an oncology specialist investor which selects and matures early-stage breakthrough inventions.

Aglaia Biomedical Ventures B.V. is a private equity and venture capital firm specializing in investments in incubation, startup, early stage, private investment in public equity (PIPEs), bridge financing, companies.

History

Aglaia Biomedical Ventures B.V. was founded in 2003 by Mark Krul and Karl Rothweiler and is based in Bilthoven, the Netherlands. The firm invests in life science companies.



The company, which currently has three funds under management, differs from other funds in that it focuses exclusively on oncology, as well as by getting involved at an early stage of technological development and through its hands-on management and allocation of capital.



Aglaia has a revenue of $1.4Million , focuses on oncology and invests in novel tools and technologies as well as components of contemporary drug development.

Investments

Aglaia BioMedical Ventures has made 8 investments, has had 1 exit, which was Merus.



Aglaia has raised a total of $65M in a single venture fund, Aglaia Oncology Fund II. This fund was announced on Sep 18, 2014, and raised a total of $65M.

Aglaia Oncology Funds

  • Aglaia Oncology Fund B.V.
  • Aglaia Oncology Seed Fund B.V.
  • Aglaia Oncology Fund II B.V.

Through its Oncology Funds I and II, Aglaia has invested in 12 early stage companies, 6 of which were founded by Aglaia. The Aglaia team has been involved in the development of more than 100 oncology products.



Aglaia's goal is to have continuous strategic and operational involvement with portfolio companies in order to de-risk and mature them up to the level at which they become attractive candidates for licensing, acquisition or IPO.

Investment Criteria

  • Early-stage oncology drug development
  • Disruptive science with the potential to transform cancer diagnosis and therapy
  • Spread across different drug modalities (small molecules, biologicals, etc.) and drug development phases (from target discovery up to clinical development)
  • It focuses on investments in tools and technologies as well as components of contemporary drug development in biomedical companies in the field of oncology and in biotechnology companies.
  • It invests in companies offering therapies for the prevention and cure of cancer. It usually invests in companies based in Europe.
  • The firm typically invests up to EUR8 million (USD10.28 million) in the companies. It prefers to take an active role in the strategic and operational processes of its portfolio companies.
  • They derive their opportunities from research centers as well as from corporate spinouts then select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.

Strategy

Aglaia identifies opportunities in cancer research and, in partnerships with inventors and entrepreneurs, takes these opportunities to the next phase of technical and commercial development.



Aglaia offers portfolio companies support in designing research and development plans, ranging from early screening and animal feasibility studies through clinical studies.



Technologies meeting the following criteria are eligible for further evaluation:

  • Fit within the focus area of oncology
  • Sustainable technological advantage
  • Above average business potential
  • Sound intellectual property protection or potential for patenting
  • Clearly definable milestones for development
  • Scientist's commitment and dedication
  • Foreseeable exit potential.



Timeline

April 10, 2018

Mimetas

Series B - Mimetas

$28.9M

May 30, 2017

Inthera Bioscience

Series A - Inthera Bioscience

CHF10.5M

January 18, 2017

Cristal Therapeutics

Venture Round - Cristal Therapeutics

€12.8M

January 8, 2017

Macrophage Pharma

Series A - Macrophage Pharma

£9M

December 14, 2015

InteRNA Technologies

Series A - InteRNA Technologies

$10.5M

December 13, 2015

Inthera Bioscience

Seed Round - Inthera Bioscience

€3.4M

September 17, 2014

Aglaia Oncology Fund II

$65M

January 28, 2010

Merus

Series B - Merus

€21.7M

Funded Companies

1 Result
Company
Company
Website
Website
Industry
Industry
Location
Location

People

Name
Role
LinkedIn

Alan Barge

Advisory Board



Angelique Hermeling

Office Manager



Eric van der Putten

Partner



Ernst Geutjes

Associate



Gabriele Dallmann

Advisory Board



Herman Spolders

Advisory Board



Karl Rothweiler

Co-founder, Partner



Kees Melief

Advisory Board



Mark Krul

Founder, Partner



Further reading

Title
Author
Link
Type
Date

Concept buy Aquila inks immuno-oncology deal with Macrophage Pharma | FierceBiotech



Web



Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer | Aglaia Oncology Funds

Aglaia Oncology Funds

Web



Dr. Axel Mescheder appointed CEO of Cristal Therapeutics as focus intensifies on proprietary oncology nanomedicine pipeline | Aglaia Oncology Funds

Aglaia Oncology Funds

Web



Dutch VC Aglaia BioMedical Ventures Invests in Swiss Biotech Inthera Bioscience



Web



InteRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting | Aglaia Oncology Funds

Aglaia Oncology Funds

Web



InteRNA Presents Expanded Preclinical Proof-of-concept Data on Lead Oncology Development Candidate INT-1B3 at the 14th Annual OTS Meeting | Aglaia Oncology Funds

Aglaia Oncology Funds

Web



Inthera Bioscience AG Expands Management Team with Seasoned Professionals and Secures €4.7 Million Second Tranche of €9.6 Million Series A Financing



Web



Inthera Bioscience AG expands management team with seasoned professionals and secures €4.7 million second tranche of €9.6 million Series A financing | Aglaia Oncology Funds

Aglaia Oncology Funds

Web



Inthera Bioscience wirbt 9,6 Mio. EUR ein



Web



ISA Pharmaceuticals' Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018 | Aglaia Oncology Funds

Aglaia Oncology Funds

Web



Macrophage Pharma Announces Appointment of Leading International Scientific Advisory Board | Aglaia Oncology Funds

Aglaia Oncology Funds

Web



Macrophage Pharma Appoints Dr Michael Moore as Chairman | Aglaia Oncology Funds

Aglaia Oncology Funds

Web



MIMETAS Secures 20 Million Dollar Series B Financing | Aglaia Oncology Funds

Aglaia Oncology Funds

Web



Modra Pharmaceuticals Expands Management Team and Provides Corporate Update | Aglaia Oncology Funds

Aglaia Oncology Funds

Web



The Good, the Bad and the Cancer-Fighting Macrophage



Web



Documentaries, videos and podcasts

Title
Date
Link

Business Analyst Positions (Industry Careers For PhDs Podcast) | Cheeky Scientist® | Industry Training For Intelligent People

22 June 2017

Companies

Company
CEO
Location
Products/Services

Cristal Therapeutics







InterRNA Technologies







Inthera Bioscience







ISA Pharmaceuticals







Macrophage







Merus







Mimetas







Modra







ORCA Therapeutics







Sapreme Technologies







Somantix







Syntarga







References